Ocriplasmin

Ocriplasmin is a protease enzyme that is used in the treatment of vitreomacular adhesion. It is marketed under the brand name Jetrea.

Etymology

The name "ocriplasmin" is derived from the Greek words "okris", meaning "sharp" or "pointed", and "plasma", meaning "something formed or molded". This refers to the enzyme's ability to break down proteins in the eye, which can help to treat certain eye conditions.

Medical Uses

Ocriplasmin is used in the treatment of vitreomacular adhesion, a condition in which the vitreous gel in the eye adheres abnormally to the retina. This can cause symptoms such as distorted vision and difficulty reading. Ocriplasmin works by breaking down the proteins that cause the vitreous gel to stick to the retina, allowing it to detach more easily.

Pharmacology

Ocriplasmin is a protease enzyme, which means it breaks down proteins. In the case of vitreomacular adhesion, the proteins that cause the condition are fibronectin and laminin. Ocriplasmin breaks these proteins down, which helps to detach the vitreous gel from the retina.

Side Effects

Like all medications, ocriplasmin can cause side effects. These can include eye pain, blurred vision, and temporary vision loss. In rare cases, it can also cause severe vision loss or detachment of the retina.

Related Terms

• Protease: A type of enzyme that breaks down proteins.
• Vitreous gel: A clear, jelly-like substance that fills the eye.
• Retina: The light-sensitive layer of tissue at the back of the eye.

Ocriplasmin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia